-+ 0.00%
-+ 0.00%
-+ 0.00%

BeOne Medicines to Present Phase 1 Liver Cancer Drug Data at ESMO 2026

PUBT·10/19/2026 10:02:00
Listen to the news
BeOne Medicines to Present Phase 1 Liver Cancer Drug Data at ESMO 2026
  • BeOne Medicines will present solid-tumor clinical data at the ESMO Congress in Madrid, October 23-27, 2026.
  • Updated Phase 3 HERIZON-GEA-01 results will evaluate Ziihera with chemotherapy, with or without Tevimbra, for first-line HER2-positive advanced gastroesophageal cancer.
  • Early-stage presentations will cover BGB-B2033 in liver cancer, BG-C477 in non-small cell lung cancer, and BGB-58067 in MTAP-deficient tumors.
  • A trial-in-progress presentation will outline KANDELA-302, comparing BGB-43395 with CDK4/6 inhibitors, each combined with letrozole, in first-line advanced HR-positive/HER2-negative breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190600BIZWIRE_USPR_____20261019_BW083871) on October 19, 2026, and is solely responsible for the information contained therein.